The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making

Sophie I. Mavrogeni1, Maya Buch2, George Markousis-Mavrogenis1, Bianca Dumitru2, Nicola Riccardo Pugliese3, Luna Gargani4

Abstract

Cardiac involvement in systemic sclerosis (SSc-CI) may be either primary or secondary to pathologic processes in other organs. In contrast to other autoimmune rheumatic diseases, primary SSc-CI preferentially manifests as non-ischemic myocardial fibrosis, with or without myocardial inflammation and minimal involvement of epicardial coronary arteries. Recent developments in cardiovascular (CV) imaging modalities and their increasing availability necessitate the creation of concrete recommendations for use in SSc patients, based on the most recent scientific evidence. Echocardiography offers rapid, effective, multiparametric, and widely available imaging evaluation of SSc patients, owing to its ability to analyze both left and right chambers, as well as pulmonary hemodynamics. However, it is an operator- and acoustic window-dependent modality that cannot perform tissue characterization, which is crucial in these conditions. CV magnetic resonance in SSc patients can accurately evaluate biventricular volumes, ejection fractions, myocardial fibrosis load, and changes suggestive of myocarditis. T2 mapping is the best index of edema indicating acute myocardial inflammation, while late gadolinium enhancement is an index of replacement fibrosis. Extracellular volume fraction (ECV) is an indicator of diffuse myocardial fibrosis only in the absence of significant myocardial inflammation. However, if myocardial inflammation/fibrosis coexist, ECV reflects a combination of the two, but it cannot completely discriminate between them. SSc-CI hangs like the sword of Damocles over physicians managing SSc patients. A constructive partnership between the rheumatologist and the cardiologist is necessary to provide each SSc patient with a comprehensive screening protocol for early detection and treatment of cardiopulmonary pathologic processes.

Keywords: Echocardiography, cardiovascular magnetic resonance, systemic sclerosis, oedema, fibrosis, myocarditis, myositis

Introduction

Systemic sclerosis (SSc) or scleroderma is an autoimmune rheumatic disease, typified by the triad of autoimmune activation, vasculopathy, and progressive fibrosis of the skin and internal organs (1). Although officially labeled a rare disease, recent epidemiologic evidence suggests that SSc affects more than two million patients worldwide, with approximately 300,000 new cases diagnosed each year (1). The systemic component of SSc refers to the involvement of major organs, those most often being the lungs and kidneys. However, SSc may also involve the cardiovascular (CV) system, which currently represents a significant contributor to mortality in this patient group (2).

Clinical manifestations of cardiac involvement in SSc

Cardiac involvement in SSc (SSc-CI) may be either primary or secondary to pathologic processes in other major organs (e.g., pulmonary or renal involvement). In contrast to other autoimmune rheumatic diseases mainly characterized by the occurrence of ischemic CV disease (CVD), primary SSc-CI preferentially manifests as non-ischemic myocardial fibrosis, with or without myocardial inflammation and minimal or no involvement of epicardial coronary arteries (3). SSc patients may thus present with myocarditis, heart failure (systolic or more commonly diastolic dysfunction), conduction abnormalities, and/or pericardial and valvular disease (3).

Mild diastolic dysfunction is present in a significant proportion of SSc patients, whereas restrictive cardiomyopathy leading to severe diastolic dysfunction has been rarely documented (4). Systolic dysfunction...
is relatively uncommon, usually occurring as a consequence of coronary artery disease or more commonly in the context of myocarditis and/or myocardial fibrosis (5). Cardiac conduction abnormalities including supraventricular/ventricular arrhythmias and/or atrioventricular block may be present in up to a third of SSc patients, and are associated with increased mortality (4). Small or moderate pericardial effusions and rarely pericardial tamponade or constrictive pericarditis have also been reported in SSc patients (6). Valvular disease in the form of valvular leaflet thickening and valve prolapse, as well as non-infectious endocarditis has been rarely documented in SSc patients (7).

**Aetiopathogenesis of cardiac involvement in SSc**

The hallmark of SSc-CI is myocardial fibrosis with or without the presence of inflammation (4). The most prevalent hypothesis is a vascular mechanism underlying the fibrotic process (8). Microvasculopathy is one of the earliest pathological features of SSc, often preceding but likely contributing to the fibrotic pattern of SSc and underlying the clinical manifestation of Raynaud phenomenon and pulmonary hypertension (PH). Similarly, repeated focal microvascular ischemia and reperfusion is thought to underlie myocardial fibrosis and diastolic dysfunction (8). More recently, the presence of myocardial inflammation in the early stages of the disease has been reported, suggesting that fibrotic processes may be preceded by inflammatory changes (7).

**Current criteria according to rheumatologists to diagnose SSc cardiac involvement**

**Identification of patients necessitating a high index of suspicion**

Epidemiologic studies have identified the following risk factors for the development of SSc-CI: (a) diffuse cutaneous SSc, (b) anti-topoisomerase antibody (anti-Scl70) seropositivity, (c) male gender, (d) presence of myositis, (e) interstitial lung disease (ILD), and (f) tendon friction rubs (5). These factors can be employed in clinical practice to maintain a higher index of suspicion in these specific patient subgroups. The presenting symptoms of SSc-CI are broad and typically comprised of dyspnea, peripheral edema, fatigue, chest pain, palpitations, or syncope. Additionally, routine annual echocardiographic monitoring for PH may identify incidental early myocardial changes.

**Further evaluation of suspected primary cardiac involvement in SSc patients**

If SSc-CI is suspected owing to any of the aforementioned reasons, further assessment is necessary. However, few recommendations are available for guiding clinical practice. The initial UK SSc working group practice guidelines were mainly based on expert opinion and lacked widespread substantiation by scientific evidence (9). Management of traditional cardiovascular risk factors is advocated as per standard practice. Recommendations for the use of electrocardiography (ECG), Holter monitoring, plasma cardiac biomarkers, echocardiography, and CV magnetic resonance (CMR) are also provided. Nevertheless, an integrated, up-to-date, evidence-based approach to diagnostic considerations in SSc-CI is still needed.

**Current gaps in evidence and the purpose of this review**

Recent technological developments in non-invasive CV imaging modalities as well as their increasing availability necessitate the generation of concrete clinical practice guidelines for their use in the SSc patient population, based on the most recent scientific evidence. This, in turn, may allow the optimization of screening, early identification, risk stratification, and reduction of associated mortality of SSc-CI, as well as the introduction of tailored treatment based on diagnostic findings. The purpose of this narrative review is to present available evidence on non-invasive CV imaging modalities and their use in SSc-CI, as well as implications for current practice and future research.

**Echocardiography in systemic sclerosis**

Echocardiography offers the advantage of non-invasive, real-time evaluation of cardiac structure and function, together with the ability to estimate pulmonary artery pressure (PAP) and other non-invasive hemodynamic measurements.

PH is defined as resting mean PAP ≥25 mm Hg, measured invasively, and is a frequent finding in SSC patients (10). PH may be the result of an isolated pulmonary arteriopathy, but also the consequence of ILD or left ventricular (LV) systolic/diastolic dysfunction (11). Different etiologies are associated with distinct pulmonary and systemic hemodynamics. Then, the task of the clinician is to make the correct diagnosis, to choose specific therapeutic management, and improve patient prognosis, keeping in mind that multiple mechanisms can coexist and overlap. Early diagnosis of PH or cardiac involvement in SSC is pivotal because identification at early stages may confer a better prognosis. However, it should be noted that lung computed tomography is the gold standard evaluation for the assessment of pulmonary pathology, particularly in cases where concomitant cardiac involvement may need to be excluded in patients at high risk of progression.

**Standard echocardiography**

Resting 2D echocardiography (2DE) in SSC patients allows the indirect assessment of systolic PAP (PAPs) and a thorough evaluation of cardiac morphology and function (11) (Table 1). PAPs measurement is based on the peak tricuspid regurgitation velocity (TRV) and right atrial pressure (RAP) estimation, which, in turn, is derived from the diameter of
| Technique                              | Parameter          | Advantages                                                                 | Limitations                                                                 |
|---------------------------------------|--------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 2D linear measurements                | EDD, ESD, IVS, ILW, LVMI, RWT | Simple<br>Allows perpendicular orientation to the LV long axis | Measurements are representative of LV size only in normal shaped ventricles |
| 2D volumes                            | EDV, ESV, LAVI, EF | Less geometrical assumptions compared with linear measurements | Reconstruction from only two different views (apical four-chamber and two-chamber planes)<br>Apex foreshortening<br>Endocardial dropout |
| 3D volumes and mass                   | EDV, ESV, LAVI, EF, LVMI | No geometrical assumptions<br>Unaffected by foreshortening<br>More accurate and reproducible than 2D when compared to cardiac magnetic resonance | Time consuming<br>Low temporal resolution<br>Image-quality dependent<br>Needs specific 3D equipment and training for offline analysis |
| Speckle-tracking                      | Peak GLS          | Angle independent | Time consuming<br>Vendor dependent<br>Needs specific software and training for offline analysis |

### RV/RA size and function

| Technique                     | Parameter          | Advantages                                                                 | Limitations                                                                 |
|-------------------------------|--------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 2D linear measurements        | RVOT, RVD1, RVD2, RVD3, TAPSE | Simple and reproducible<br>Established prognostic value | Single-site measurement may underestimate RV size due to the complex geometry of the RV<br>Require RV-focused apical four chamber view to reduce variability<br>Angle dependency<br>Partially representative of RV global function |
| Tissue Doppler Imaging        | S'-wave            | Simple and reproducible<br>Established prognostic value | Angle dependency<br>Partially representative of RV global function |
| 2D areas                      | Fractional Area Change | Relatively easy to measure | Frequent suboptimal RV endocardial definition<br>Low inter-observer reproducibility<br>LV twisting motion and RV crescent shape affect the end-diastolic and end-systolic tomographic-plane alignment<br>Partially representative of RV global function |
| 3D volumes                    | EDV, ESV, RAVI, EF | No geometrical assumptions<br>Inclusion of RV global size: inflow, apical and outflow tracts<br>More accurate and reproducible than 2D when compared to cardiac magnetic resonance | Low temporal resolution<br>Image-quality dependent<br>Needs specific 3D equipment and training for offline analysis |
| Speckle-tracking              | Peak GLS          | Angle independent | Time consuming<br>Vendor dependent<br>Needs specific software and training for offline analysis<br>Few publications |
Because of the inaccuracy of RAP estimation, guidelines recommend using peak TRV as the primary variable for assigning the echocardiographic probability of PH (10), taking into account that underestimation [e.g., severe tricuspid regurgitation or right ventricular (RV) systolic dysfunction] or overestimation (e.g., errors in adjusting Doppler gain) may also occur (12). Other echocardiographic variables may be considered for confirming a suspicion of PH, such as an enlarged RV and right atrium with dilated pulmonary artery diameter, RV outflow Doppler acceleration time <105 ms with a mid-systolic notching, or a systolic flattening of the interventricular septum due to pressure overload imposed on the RV (10).

Echocardiographic LV evaluation is well-established and reliable, as extensively described in international recommendations (12), but a comprehensive assessment of RV structure and function in SSc is advisable. RV measurements are challenging, owing to the complex geometry of this chamber. A 2DE RV-focused apical four-chamber view obtained with either lateral or medial transducer orientation is advisable for reducing inter-reader variability (Figure 1). Increased basal and midlevel diameters indicate RV dilatation; likewise, the right atrium can be assessed from the same view, measuring the area or volume (13). RV free-wall thickness in the subcostal view should also be evaluated, because the RV develops concentric hypertrophy in response to pressure overload during the adaptation phase that precedes heart failure (13). RV systolic function can be roughly assessed using the longitudinal excursion of the tricuspid annular plane systolic excursion (TAPSE). TAPSE has the advantage of being simple, independent of RV preload, and related to stroke volume.
(12). Tissue-Doppler-imaging-derived S’-wave velocity of tricuspid lateral annular velocity is another reliable and reproducible parameter for expressing RV systolic function (14), even though it is angle-dependent. However, both TAPSE and S’-wave do not represent global RV performance (12). Fractional area change during the cardiac cycle can offer a more comprehensive assessment of RV systolic function, but neglects the contribution of the RV outflow tract to overall systolic function and has low inter-observer reproducibility. 3D-echocardiography (3DE) derived volumetric measurements are more robust and accurate compared with 2D linear dimension delineation in assessing cardiac structure and function (12), making 3DE the preferred approach. Nevertheless, a thorough echocardiographic evaluation, although highly advised, may sometimes not be possible to perform owing to patient constraints, lack of expertise, or lack of appropriate analytic software. In this case, a core set of basic parameters that can guide the clinician to refer patients to more specialized centers should at least include the parameters presented in Figure 2.

Finally, the addition of lung ultrasound to conventional transthoracic 2DE is relatively time-saving and has incremental value in identifying the etiology of PH (11). Indeed, the presence of multiple, diffuse, bilateral B-lines with a regular pleural line and a gravity-related distribution can corroborate the diagnosis of decompensated left heart failure, as a sign of pulmonary congestion (15). In contrast, a normal LV scan with multiple, diffuse B-lines and an irregular pleural line are highly suggestive for ILD (16).

Exercise echocardiography

The study of pulmonary hemodynamics during exercise is fascinating and challenging at the same time. Right heart catheterization is the gold standard for assessing PH at rest and during exercise, but exercise echocardiography represents a non-invasive tool with evolving clinical applications (11). Exercise PH can be defined as the presence of resting mean PAP<25 mm Hg and mean PAP>30 mm Hg during exercise, with pulmonary vascular resistance (PVR) greater than 3 Wood units (10). It represents the result of early pulmonary vascular disease, left heart disease, lung disease, or a combination of these conditions. As all these mechanisms may evolve and/or coexist in SSC, exercise echocardiography could be useful in evaluating pulmonary hemodynamics as well as the state of the left and right heart chambers.

It is essential to consider that exercise PH in SSC patients is dependent not only on PVR but also on LV filling pressure (17). Echocardiography may help identify the relative hemodynamic contribution of each parameter during exercise to better understand the main determinants of increased PAP, unveiling early signs of LV or RV dysfunction (18). However, even though exercise PH has a high prevalence in SSC patients, only a small proportion go on to develop PH during follow-up (19). Additionally, PH does not occur over time in SSC patients without exercise PH (20). So far, there is a lack of robust clinical evidence on targeted medical therapy for exercise PH, as recognized by the latest European Guidelines (10). Larger studies are needed to test the value of exercise echocardiography in assessing the pathologic background of altered pulmonary hemodynamics in SSC and determining its role in detecting patients with a very low probability of developing PH.

New frontiers: 3DE and STE

3DE overcomes the limitations of conventional 2DE, providing an accurate reconstruction of LV and RV volumes. Dedicated single-beat or multi-beat 3D acquisition software is available for evaluating the left and right cardiac chambers without geometric assumptions; specific training in image post-processing and analysis is required for their operation. Although 3DE tends to underestimate cardiac volumes in comparison with CMR, the gold standard for right heart evaluation (21), the correlation between 3DE and CMR is significantly higher than that between 2DE and CMR (22).

Speckle tracking echocardiography (STE) provides a useful assessment of both LV and RV global and regional systolic function (23). 2DE-STE is influenced by image quality and frame rate, but is independent of the angle of insonation. Peak LV global longitudinal strain (GLS) reflects the deformation of all LV segments and represents the most robust and reproducible STE-derived parameter in various cardiac diseases, including SSC (23). In the context of the RV, GLS usually refers to the RV free wall seg-
detection of subclinical deterioration or the evaluation of medication effectiveness in clinical trials with SSc patients (21).

**Evaluation of inflammation:** CMR excels at evaluating inflammation, owing to its ability to characterize myocardial tissues. In order to perform CMR, a strong magnetic field is used to polarize hydrogen atoms in the body so that their magnetic moments (vectors perpendicular to their angular momentum) align along the same axis, either parallel or anti-parallel to the magnetic field. A radiofrequency photon pulse is then emitted, which provides additional energy for the protons to transition from the low-energy state (parallel) to the high-energy state (anti-parallel). As the protons start to return to the lower energy state, they re-emit the energy they absorbed in the form of photons, which are used by a detector to digitally reconstruct an image. Protons have two ways of returning to their original position, the so-called longitudinal relaxation and transverse relaxation. The average amount of time required for longitudinal relaxation (T1) and transverse relaxation (T2) differs according to the composition of each tissue and can thus be used to characterize myocardial tissues essentially on the basis of their proton content (25).

CMR is the only non-invasive imaging modality capable of detecting myocardial inflammation, before functional changes start to occur (e.g., in LV and RV volumes and ejection fractions). Combined with the use of a paramagnetic gadolinium-based contrast agent, CMR provides a fundamental contribution to the diagnosis of myocarditis using three types of images: T2-weighted (T2-W) images, early T1-weighted (T1-W) images (early gadolinium enhancement [EGE]), and delayed enhanced images (late gadolinium enhancement [LGE]) (the former taken after 1 min and the latter after 10-20 min following the injection of paramagnetic contrast agent).

According to Lake Louise criteria for the diagnosis of myocarditis, the myocardial to skeletal muscle T2-signal ratio, as well as EGE and LGE imaging should be evaluated before reaching a diagnostic conclusion. The examination is considered as positive for myocarditis, if 2/3 of the examined indices are positive (26). These criteria have been successfully used for acute myocarditis detection, with sensitivities and specificities ranging from 53% to 92% and 57% to 95%, respectively. However, lower values were seen when endomyocardial biopsies (EMBs) were used as reference standard instead of clinical/angiographic findings (26). In an EMB-based study, Lurz et al. (27)
used as an indicator of myocardial edema in Lake Louise criteria (31). 

3. T2 mapping: This is a pure quantitative approach. Normal myocardial T2-mapping values, acquired using steady-state free precession imaging, have been reported to be $52.18\pm3.4$ ms using a 1.5T magnetic field (32) and $51.6\pm3$ ms using a 3T magnetic field (33).

**EGE**

EGE describes the phenomenon of regional vasodilatation, increased blood flow, and capillary leakage usually occurring in inflammatory processes. These phenomena lead to increased paramagnetic contrast retention in the early washout period, resulting in prolongation of T1 relaxation times (34). Analysis of EGE images is commonly performed using the global relative enhancement (gRE), which is calculated as myocardial SI divided by skeletal muscle SI. Most studies use a gRE value of 4.0 as the threshold between healthy and abnormal myocardium (35).

The sensitivity, specificity, and diagnostic accuracy of EGE for diagnosing acute myocarditis are 66%, 70%, and 67%, respectively, with a wide range of diagnostic performances reported for both myocardial signal enhancement and gRE analysis techniques. Interestingly, Bohnen et al. (36) found no statistical difference in gRE between heart failure patients with histologically confirmed inflammation and those without. gRE values significantly decrease between acute and convalescent phases of myocarditis (37). EGE may also be an index of area at risk of both reversible and irreversible cardiac lesions post-acute myocardial infarction (38).

**LGE**

CMR can detect and quantify replacement-type myocardial fibrosis, due to irreversible myocardial damage (viability study). The preferred imaging time for replacement fibrosis detection is between 10 and 20 min after paramagnetic contrast agent administration, when the contrast agent concentrations in the different tissue compartments have reached a steady state. This method is referred to in the literature as LGE CMR and is the diagnostic gold standard for the assessment of replacement-type fibrosis in vivo (Figure 4) (39). CMR can detect fibrosis in as little as $1$ cm$^2$ of tissue, thus having significantly higher spatial resolution than other in vivo methods of evaluation, such as echocardiography and nuclear imaging modalities. CMR also has excellent agreement with histologic findings in both animal and human studies (39). However, SSC may be accompanied by diffuse interstitial-type myocardial fibrosis next to the replacement-type identified by LGE (39).

**Native T1 mapping**

Native T1 is a promising method for the detection of myocardial abnormalities without the need for administration of paramagnetic contrast agents. Normal myocardial native T1 values, acquired using the modified look-locker inversion recovery magnetic resonance (MR) method, have been reported to be $930\pm21$ ms and $1052\pm23$ ms at a magnetic field strength of 1.5T and 3T, respectively (40). The native T1 value of the myocardium is also dependent on age and sex with men and older subjects having slightly higher values than women and younger subjects (41). Pathologic processes can alter either the water composition or the molecular environment of the myocardium and consequently alter T1 relaxation time in diffuse interstitial fibrosis, edema, and inflammation (42, 43).

**Extracellular volume fraction values**

The myocardium can be divided into its cellular and extracellular or interstitial components. The extracellular space contains interstitial free fluid, collagen fibrils, and glycoproteins (44). The interstitium is a dynamic environment of vital significance for normal cardiac function (44, 45). Extracellular space expansion is an important factor in ventricular remodeling and a potential therapeutic target. Myocardial fibrosis, a common pathologic finding of heart diseases and a major independent predictor of adverse cardiac events, is the major cause of extracellular space expansion (44). Other pathologic processes such as edema and inflammation may also cause extracellular space expansion (45). Until recently, EMB was the only available method for the quantification of diffuse fibrosis. T1 mapping sequences have enabled the non-invasive quantitative estimation of myocardial interstitial remodeling. The myocardial ECV is derived on the basis of native T1 mapping values and T1 mapping values after injection of paramagnetic contrast agent corrected for the hematocrit level, and its clinical utility has been demonstrated by several studies (43).

**CMR issues in the evaluation of SSC patients**

Specifically in SSC, several difficulties may be encountered in the evaluation of myocardial inflammation/fibrosis:
Mavrogeni et al. Cardiac imaging in SSc

a) Replacement-type myocardial fibrosis constitutes the “trademark” of SSc and thus cannot be considered as an acute myocarditis index. Distinguishing between edema and fibrosis in SSc patients is not possible even when employing T1 mapping (46). In addition, there is a great variation in LGE signal intensity, although the significance of this variation remains unknown. A signal intensity above 5 standard deviations (SD) of the normal myocardium should be considered as full intensity LGE and a grayscale analysis of intermediate-signal intensity LGE should be performed for cases with ≥2SD but <5SD of the normal myocardium (47). The presence and extent of LGE is also linked to ventricular arrhythmias in SSc patients (48).

b) In parallel with replacement fibrosis, identified by LGE in SSc, diffuse interstitial fibrosis can be also detected. The latter remains unidentified by LGE and only the new CMR indices including T1 mapping and extracellular volume index (ECV) are able to assess it (46). However, recent findings comparing ECV with EMB in inflammatory cardiomyopathies proved that the concept of ECV as an index of diffuse myocardial fibrosis is correct only in the absence of significant myocardial inflammation. Taking into account that various degrees of myocardial inflammation and fibrosis may coexist in various diseases including SSc, the measured ECV will reflect a sum of different pathologies occurring in the extracellular volume, but will not inform exclusively about the extent of diffuse fibrosis (47, 49).

c) CMR maybe not always be in agreement with EMB. However, considerations including the exact timing of CMR and/or EMB play an important role in this case. Furthermore, CMR is more suited to identification of acute inflammatory processes and may underestimate chronic inflammatory lesions (35).

Conclusion

Non-invasive CV imaging in the form of echocardiography and CMR are of paramount importance for the detection of CVD in SSc. We recommend a thorough baseline echo and, if available, a CMR evaluation at diagnosis. Serial echocardiographic evaluations are also strongly recommended, possibly every 6-12 months, according to the overall clinical picture. Patients with any change in echocardiographic parameters during follow-up or with any significant increase in myocardial necrosis biomarkers (cardiac troponins) should be immediately evaluated with CMR, and administration of relevant cardiac and anti-rheumatic medication should be promptly contemplated. CMR can be also used as a screening tool in order to avoid unnecessary coronary angiography in patients presenting with chest pain, ECG changes, and/or elevated cardiac biomarker levels.

To conclude, the indications to refer SSc patients for CMR include:

1. ECG and/or echocardiographic abnormalities necessitating further evaluation.
2. Typical or atypical cardiac symptoms not otherwise clearly explained.
3. A significant increase in myocardial stress/injury biomarkers.
4. Any mismatch between clinical symptoms and echocardiographic findings or biomarker values.
5. Evaluation/change of cardiac and anti-rheumatic medication.

Most of these indications are unfortunately not supported by solid published data yet, and up-to-date essentially reflect routine clinical experience. There is a strong need of a cooperative effort from the scientific community to provide robust evidence for the use of advanced cardiac imaging to support the management of these patients, whose natural history and specific needs in presence of SSc-CI are so different from the more common and known cardiac conditions.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - S.I.M., M.B., G.M.M., B.D., N.R.P., L.G.; Literature Search - S.I.M., M.B., G.M.M., B.D., N.R.P., L.G.; Writing Manuscript - S.I.M., M.B., G.M.M., B.D., N.R.P., L.G.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165-70. [Crossref]
2. Tyndall AJ, Bannert B, Vonk M, Arfib P, Cozzi F, Caresse PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15. [Crossref]
3. Rangarajan V, Matiasz R, Freed BH. Cardiac complications of systemic sclerosis and management: Recent progress. Curr Opin Rheumatol 2017; 29: 574-84. [Crossref]
4. Maione S, Cuomo G, Giunta A, Tanturri De Hortaio L, La Montagna G, Manguso F, et al. Echocardiographic alterations in systemic sclerosis: A longitudinal study. Semin Arthritis Rheum 2005; 34: 721-7. [Crossref]
5. Alliance Y, Meune C, Vonk MC, Airo P, Hackula E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research Group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218-21. [Crossref]
6. Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998; 37: 1320-3. [Crossref]
7. Dinsel R, Frerix M, Meier FMP, Klingel K, Rolf A. Endocardial and myocardial involvement in systemic sclerosis - is there a relevant inflammatory component? Jt Bone Spine 2013; 80: 320-3. [Crossref]
8. Mavrogeni S, Brats K, van Wijk K, Stavropoulos E, Hautemann D, Reiber JHC, et al. Myocardial perfusion-fibrosis pattern in systemic sclerosis assessed by cardiac magnetic resonance. Int J Cardiol 2012; 159: e56-e6. [Crossref]
9. Bissell LA, Anderson M, Burgess M, Chakravarty K, Coghlan G, Dunitz RB, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: Management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 2017; 56: 912-21. [Crossref]
10. Galilei N, Humbert M, Vachery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119. [Crossref]
11. Gargani L, Voilliot D, D’Alto M, Agoston G, Moreo A, Serra W, et al. Pulmonary circulation on the crossroads between the left and right heart in systemic sclerosis. A clinical challenge for cardiologists and rheumatologists. Heart Fail Clin 2018; 14: 271-81. [Crossref]
12. Lang RM, Badano LP, Vitor MA, Afshol J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1-39.e14. [Crossref]
13. Ferrara F, Gargani L, Ruohonen S, Vriz O, Scalese M, Russo V, et al. Reference values and correlates of right atrial volume in healthy adults by two-dimensional echocardiography. Echocardiography 2018; 35: 1097-107. [Crossref]
14. Innelli P, Esposito R, Olibet M, Nistri S, Galdens M. The impact of ageing on right ventricular longitudinal function in healthy subjects: A pulsed tissue Doppler study. EUR J Echocardiogr 2009; 10: 491-8. [Crossref]
15. Gargani L, Volpicelli G. How i do it: Lung ultrasound. Eur J Echocardiogr 2018; 39: 216-30. [Crossref]
16. Wang YK, Gargani L, Banskoska T, Furst DE, Cerinic MM. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: A literature review. Arthritis Res Ther 2017; 19: 206. [Crossref]
17. Huez S, Roufousse F, Vachiery JL, Pavaleescu A, Derumeaux G, Wautelet JC, et al. Isolated right ventricular dysfunction in systemic sclerosis: Latent pulmonary hypertension? Eur Respir J 2007; 30: 928-36. [Crossref]

Eur J Rheumatol 2020; 7(Suppl 3): S203-11
Eur J Rheumatol 2020; 7(Suppl 3): S203-11

18. Gargani L, Pignone A, Agoston G, Moreo A, Capeti E, Badano LP, et al. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: A multicenter study. Am Heart J 2013; 165: 200-7. [Crossref]

19. Callejas-Rubio JL, Moreno-Escobar E, De La Fuente PM, López Pérez L, Rios Fernández R, Sánchez-Cano D, et al. Prevalence of exercise pulmonary arterial hypertension in scleroderma. J Rheumatol 2008; 35: 1812-6.

20. Voilliot D, Magne J, Dulgheru R, Kou S, Henri C, Caballero L, et al. Prediction of new onset of resting pulmonary arterial hypertension in systemic sclerosis. Arch Cardiovasc Dis 2016; 109: 268-77. [Crossref]

21. Crean A, Ballard G, Maredia N, Greenwood J, Thomson J. 3D echo systematically underestimates right ventricular volume compared to cardiac magnetic resonance in a population with adult congenital heart disease. J Cardiovasc Magn Reson 2010; 12: P18. [Crossref]

22. Van Der Zwaan HB, Geleijnse ML, McGhee JS, Boersma E, Helbing WA, Mejboom FI, et al. Right ventricular quantification in clinical practice: Two-dimensional vs. three-dimensional echocardiography compared with cardiac magnetic resonance imaging. Eur J Echocardiogr 2011; 12: 656-64. [Crossref]

23. Voigt JU, Pedrizetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: Consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2016; 16: 1-11. [Crossref]

24. Haack MLA, Scherpoting RWC, Marsan NA, Holman ER, Schalij MJ, Bax JJ, et al. Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension. Circ Cardiovasc Imaging 2012; 5: 628-36. [Crossref]

25. Mavrogeni S, Markoussis-Mavrogenis G, Koutsogeorgopoulou L, Kolovou G. Cardiac magnetic resonance imaging: Clinical implications in the evaluation of connective tissue diseases. J Inflamm Res 2017; 10: 55-61. [Crossref]

26. Esposito A, Francone M, Faletti R, Centonze M, Cademartiri F, Carbone I, et al. Lights and shadows of cardiac magnetic resonance imaging in acute myocarditis. Insights Imaging 2016; 7: 99-110. [Crossref]

27. Lurz P, Luecke C, Eitel I, Föhenbach F, Frank C, Grothoff M, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: The myoracer-trial. J Am Coll Cardiol 2016; 67: 1800-11. [Crossref]

28. Zhang Y, Corona-Villalobos CP, Kiani AN, Eng J, Kamel IR, Zimmerman SL, et al. Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging 2015; 31: 389-97. [Crossref]

29. Nadjiiri J, Hendrich E, Will A, Pankalla C, Schehu N, Martinoff S, et al. Performance of native and contrast enhanced T1 mapping to detect myocardial damage in patients with suspected myocarditis: A head to head comparison of different CMR-techniques. J Cardiovasc Magn Reson 2015; 17: 086. [Crossref]

30. Mavrogeni S, Koutsogeorgopoulou L, Karabela G, Stavropoulos E, Katsifis G, Raffakis J, et al. Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria. BMC Cardiovasc Disord 2017; 17: 187. [Crossref]

31. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakja P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol 2009; 53: 1475-87. [Crossref]

32. Gin S, Shah S, Xue H, Chung YC, Pernell ML, Guerhing J, et al. Myocardial T2 mapping with respiratory navigator and automatic nonrigid motion correction. Magn Reson Med 2012; 68: 1570-8. [Crossref]

33. Von Knobelsdorff-Benkenhoff F, Prothmann M, Dieringer MA, Wasmuth R, Greiser A, Schwenke C, et al. Myocardial T1 and T2 mapping at 3T: Reference values, influencing factors and implications. J Cardiovasc Magn Reson 2013; 15: 53. [Crossref]

34. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches. J Am Coll Cardiol 2005; 45: 1815-22. [Crossref]

35. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging 2012; 5: 513-24. [Crossref]

36. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stenhning C, Schnackenburg B, et al. Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 2015; 8: e003073. [Crossref]

37. Mavrogeni S, Spargias C, Bratis C, Kolovou G, Markoussis VM, Loudon M, et al. Human non-contrast T1 mapping as a potential biomarker for cardiac involvement in systemic sclerosis. Rheumatology (Oxford) 2019 Nov 25. doi: 10.1093/rheumatology/kez494. [Online ahead of print]. [Crossref]

38. Hammer-Hansen S, Leung SW, Hsu LY, Wilson JR, Taylor J, Greve AM, et al. Early gadolinium enhancement for determination of area at risk: A preclinical validation study. JACC Cardiovasc Imaging 2017; 10: 130-9. [Crossref]

39. Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel S, et al. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. Int J Cardiol 2016; 217: 135-48. [Crossref]

40. Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, et al. Reference values for healthy human myocardium using a T1 mapping methodology: Results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2014; 16: 69. [Crossref]

41. Piechnik SK, Feirera VM, Lewandowski AJ, Ntusi NA, Banerjee R, Holloway C, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLL. J Cardiovasc Magn Reson 2013; 15: 13. [Crossref]

42. Bull S, White SK, Piechnik SK, Flett AS, Feirera VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 2013; 99: 932-7. [Crossref]

43. Mavrogeni S, Apostolou D, Argiropoulou P, Veiltissta S, Papa L, Efentakis S, et al. T1 and T2 mapping in cardiology: “Mapping the obscure object of desire.” Cardiology 2017; 138: 207-17. [Crossref]

44. Spinaule FG, Frangogiannis NG, Hinz B, Holmes JW, Kassis Z, Lindsey ML. Crossing into the next frontier of cardiac extracellular matrix research. Circ Res 2016; 119: 1040-5. [Crossref]

45. Dongaonkar RM, Stewart RH, Geissler HJ, Laine GA. Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc Res 2010; 87: 331-9. [Crossref]

46. Mavrogeni SI, Schwitter J, Gargani L, Pepe A, Monti L, Allanoire Y, et al. Cardiovascular magnetic resonance in systemic sclerosis: “Pearls and pitfalls.” Semin Arthritis Rheum 2017; 47: 79-85. [Crossref]

47. Krumm F, Mueller KAL, Klingel K, Kramer U, Horger MS, Zitzelsberger T, et al. Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis. J Cardiovasc Magn Reson 2016; 18: 70. [Crossref]

48. Mavrogeni SI, Gargani L, Pepe A, Monti L, Markoussis-Mavrogenis G, De Santis M, et al. Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: The Sclerodermia Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology (Oxford) 2019 Nov 25. doi: 10.1093/rheumatology/kez494. [Online ahead of print]. [Crossref]

49. Lurz JA, Luecke C, Lang D, Besler C, Rommel KP, Klingel K, et al. CMR-derived extracellular volume fraction as a marker for myocardial fibrosis: The importance of coexisting myocardial inflammation. JACC Cardiovasc Imaging 2018; 11: 38-45. [Crossref]